Randomized Double Blind Placebo Controlled Multicent Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects

Grants and Contracts Details

StatusFinished
Effective start/end date1/1/0512/31/06

Funding

  • AstraZeneca Pharmaceuticals AB: $15,830.00